Medicines for Europe, a trade group for the European generics and biosimilars industry, has welcomed the position adopted today by the European Parliament regarding SPC regulation.
The European generics industry has for some time campaigned for various changes to the rules governing Supplementary Protection Certificates (SPC).
SPCs allow drugmakers to extend the 20-year patent protection on their medicines by an additional five years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze